Search

CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting...

CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications


...""We are leveraging our validated drug technology platform, currently in use in a variety of consumer markets as well as our CUREfilm® Blue clinical program, to enhance shareholder value via this pipeline expansion," said Rob Davidson, CEO of CURE. "As we looked to expand our pharmaceutical pipeline, we used a very methodical approach to product selection, striving to best differentiate ourselves as a pharmaceutical researcher and product developer. By working with known APIs and applying them using our CUREform™ platform, similar to how we have approached our Sildenafil program, we amplify our market opportunities in an important and relevant way by increasing the probability of approval and speed to market..."


031021 Cure News Release
.pdf
Download PDF • 95KB